Intersect ENT’s PROPEL Mini Sinus Implant Gains Additional Indication

Intersect ENT won FDA approval for an expanded indication for the PROPEL mini steroid releasing sinus implant for frontal sinus disease.

With the expanded indication, the device can now be implanted in the frontal sinuses in patients undergoing frontal sinus surgery. Initially, the device was only indicated for ethmoid sinuses.

In clinical trials, patients using the device post-surgery experienced a 38 percent reduction in need for overall post-operative intervention compared with surgery alone. — Anisa Jibrell